In addition, TTC ≥91 days was shown to be associated with an increased risk in BC-specific death only in TNBC patients (HR, 1.53, 95% CI, 1.17–2.07), but not in patients with HR-positive or HER2-positive tumors12. This evidence concerns the gene ERBB2 and breast cancer.